MethylCCNU

Methyl-CCNU, also known as Lomustine or CCNU, is a medication used in chemotherapy. It belongs to a class of drugs called nitrosoureas, which are alkylating agents. These agents work by damaging the DNA of cancer cells, preventing them from dividing and growing. Methyl-CCNU is an orally administered drug, meaning it is taken by mouth.

It is primarily used to treat brain tumors, including glioblastoma multiforme, and is also employed in the treatment of Hodgkin's lymphoma and non-Hodgkin's lymphoma. Its lipophilic nature allows it to cross the blood-brain barrier, making it particularly effective for central nervous system cancers. The dosage and treatment regimen are determined by the specific type and stage of cancer, as well as the patient's overall health.

Like many chemotherapy drugs, Methyl-CCNU can cause significant side effects. Common adverse effects include nausea and vomiting, bone marrow suppression leading to decreased blood cell counts (which can increase the risk of infection and bleeding), hair loss, and fatigue. Less common but more serious side effects can include lung toxicity and kidney damage. Due to its potential toxicity, patients undergoing treatment with Methyl-CCNU are closely monitored by their healthcare providers. Research into its efficacy and potential for combination therapies continues.